$LSTA
LISATA THERAPEUTICS, INC.

2020 Q4 Form 10-Q Financial Statement

#000032001720000110 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.540M $2.321M $2.068M
YoY Change 9.48% 12.23% 0.29%
% of Gross Profit
Research & Development $2.910M $3.029M $3.004M
YoY Change 5.05% 0.83% 76.6%
% of Gross Profit
Depreciation & Amortization $10.00K $20.00K $10.00K
YoY Change -50.0% 100.0% -75.0%
% of Gross Profit
Operating Expenses $5.450M $5.350M $5.072M
YoY Change 7.28% 5.48% 34.79%
Operating Profit -$5.350M -$5.072M
YoY Change 5.48% 34.79%
Interest Expense $30.00K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $10.00K $25.00K $175.0K
YoY Change -92.31% -85.71% -18.22%
Pretax Income -$5.430M -$5.325M -$4.897M
YoY Change 9.7% 8.74% 37.97%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.430M -$5.327M -$4.898M
YoY Change 9.48% 8.76% 38.01%
Net Earnings / Revenue
Basic Earnings Per Share -$0.29
Diluted Earnings Per Share -$279.8K -$0.29 -$470.7K
COMMON SHARES
Basic Shares Outstanding 19.40M shares 18.60M shares 10.40M shares
Diluted Shares Outstanding 18.60M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.57M $40.27M $29.16M
YoY Change 37.43% 38.09% -36.81%
Cash & Equivalents $16.51M $21.16M $12.67M
Short-Term Investments $18.06M $19.11M $16.49M
Other Short-Term Assets $800.0K $1.000M $1.100M
YoY Change 0.0% -9.09% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $35.33M $41.26M $30.24M
YoY Change 36.03% 36.42% -36.0%
LONG-TERM ASSETS
Property, Plant & Equipment $57.00K $67.00K $115.0K
YoY Change -43.0% -41.74% -37.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $614.0K $694.0K $1.312M
YoY Change -43.2% -47.1% 213.76%
Total Long-Term Assets $671.0K $761.0K $1.427M
YoY Change -43.18% -46.67% 137.54%
TOTAL ASSETS
Total Short-Term Assets $35.33M $41.26M $30.24M
Total Long-Term Assets $671.0K $761.0K $1.427M
Total Assets $36.00M $42.02M $31.67M
YoY Change 32.59% 32.67% -33.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.020M $1.105M $844.0K
YoY Change -31.54% 30.92% 88.72%
Accrued Expenses $2.486M $3.076M $5.135M
YoY Change -44.58% -40.1% 15.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.506M $4.181M $5.979M
YoY Change -41.33% -30.07% 22.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $254.0K $351.0K $710.0K
YoY Change -59.29% -50.56% -67.01%
Total Long-Term Liabilities $254.0K $351.0K $710.0K
YoY Change -59.29% -50.56% -67.01%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.506M $4.181M $5.979M
Total Long-Term Liabilities $254.0K $351.0K $710.0K
Total Liabilities $3.760M $4.532M $6.689M
YoY Change -43.03% -32.25% -5.04%
SHAREHOLDERS EQUITY
Retained Earnings -$425.6M -$420.1M -$412.4M
YoY Change 1.95% 1.86% 4.57%
Common Stock $19.00K $19.00K $10.00K
YoY Change 72.73% 90.0% 1.49%
Preferred Stock
YoY Change
Treasury Stock (at cost) $708.0K $708.0K $708.0K
YoY Change 0.0% 0.0% 0.05%
Treasury Stock Shares 11.08K shares 11.08K shares 11.08K shares
Shareholders Equity $32.50M $37.74M $25.25M
YoY Change
Total Liabilities & Shareholders Equity $36.00M $42.02M $31.67M
YoY Change 32.59% 32.67% -33.82%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$5.430M -$5.327M -$4.898M
YoY Change 9.48% 8.76% 38.01%
Depreciation, Depletion And Amortization $10.00K $20.00K $10.00K
YoY Change -50.0% 100.0% -75.0%
Cash From Operating Activities -$5.560M -$3.520M -$4.450M
YoY Change 31.75% -20.9% -6.51%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $910.0K -$11.04M $5.380M
YoY Change -82.83% -305.2% -229.02%
Cash From Investing Activities $910.0K -$11.05M $5.380M
YoY Change -82.83% -305.39% -225.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 9.030M 0.000
YoY Change -96.3% -100.0%
NET CHANGE
Cash From Operating Activities -5.560M -3.520M -4.450M
Cash From Investing Activities 910.0K -11.05M 5.380M
Cash From Financing Activities 10.00K 9.030M 0.000
Net Change In Cash -4.640M -5.540M 930.0K
YoY Change -443.7% -695.7% -111.14%
FREE CASH FLOW
Cash From Operating Activities -$5.560M -$3.520M -$4.450M
Capital Expenditures -$10.00K $0.00 $0.00
Free Cash Flow -$5.550M -$3.520M -$4.450M
YoY Change 31.52% -20.9% -4.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0000320017
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33650
dei Entity Registrant Name
EntityRegistrantName
CALADRIUS BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
22-2343568
dei Entity Address Address Line1
EntityAddressAddressLine1
110 Allen Road, 2nd Floor
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Address City Or Town
EntityAddressCityOrTown
Basking Ridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07920
dei City Area Code
CityAreaCode
908
dei Local Phone Number
LocalPhoneNumber
842-0100
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CLBS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19395977 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21156000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14032000 USD
CY2020Q3 us-gaap Marketable Securities
MarketableSecurities
19113000 USD
CY2019Q4 us-gaap Marketable Securities
MarketableSecurities
11125000 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
989000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
815000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
41258000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
25972000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
100000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
694000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1081000 USD
CY2020Q3 us-gaap Assets
Assets
42019000 USD
CY2019Q4 us-gaap Assets
Assets
27153000 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1105000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1490000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3076000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4486000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4181000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5976000 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
351000 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
624000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
4532000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
6600000 USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2019Q4 clbs Preferred Stock Liquidation Preference Share
PreferredStockLiquidationPreferenceShare
0.001 shares
CY2020Q3 clbs Preferred Stock Liquidation Preference Share
PreferredStockLiquidationPreferenceShare
0.001 shares
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 clbs Preferred Stock Shares Designated
PreferredStockSharesDesignated
825000 shares
CY2020Q3 clbs Preferred Stock Shares Designated
PreferredStockSharesDesignated
825000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10000 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10000 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19407057 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19407057 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10528689 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10528689 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
19000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
11000 USD
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
458560000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
438911000 USD
CY2020Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
11080 shares
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
11080 shares
CY2020Q3 us-gaap Treasury Stock Value
TreasuryStockValue
708000 USD
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
708000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-420119000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-417400000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
37740000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
20816000 USD
CY2020Q3 us-gaap Minority Interest
MinorityInterest
-253000 USD
CY2019Q4 us-gaap Minority Interest
MinorityInterest
-263000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
37487000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
20553000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42019000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27153000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3029000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3004000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6346000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8030000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2321000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2068000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7353000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6980000 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
5350000 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
5072000 USD
us-gaap Operating Expenses
OperatingExpenses
13699000 USD
us-gaap Operating Expenses
OperatingExpenses
15010000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5350000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5072000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13699000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
611000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-15010000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25000 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
175000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
118000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
611000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
175000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
118000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-5325000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4897000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-13581000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14399000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10872000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-5325000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-4897000 USD
us-gaap Profit Loss
ProfitLoss
-2709000 USD
us-gaap Profit Loss
ProfitLoss
-14399000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
2000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
1000 USD
us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
10000 USD
us-gaap Income Loss From Continuing Operations Attributable To Noncontrolling Entity
IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
6000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-5327000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-4898000 USD
us-gaap Net Income Loss
NetIncomeLoss
-2719000 USD
us-gaap Net Income Loss
NetIncomeLoss
-14405000 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.40
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18597000 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10411000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14116000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10279000 shares
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-5325000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-4897000 USD
us-gaap Profit Loss
ProfitLoss
-2709000 USD
us-gaap Profit Loss
ProfitLoss
-14399000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
34000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-14000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-14000 USD
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
34000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-5339000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-4895000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-2723000 USD
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-14365000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
2000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
1000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
10000 USD
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
6000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5341000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4896000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2733000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14371000 USD
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
20553000 USD
us-gaap Profit Loss
ProfitLoss
-2709000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-14000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
942000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18715000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
37487000 USD
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
37454000 USD
us-gaap Profit Loss
ProfitLoss
-14399000 USD
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
34000 USD
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
917000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1038000 USD
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24982000 USD
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
33556000 USD
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-5325000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-5000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
229000 USD
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9032000 USD
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
37487000 USD
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
29622000 USD
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-4897000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
254000 USD
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000 USD
CY2019Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24982000 USD
us-gaap Profit Loss
ProfitLoss
-2709000 USD
us-gaap Profit Loss
ProfitLoss
-14399000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1090000 USD
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1047000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
46000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
50000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-172000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-172000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
174000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
30000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-387000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-272000 USD
clbs Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
-2068000 USD
clbs Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
-1774000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3256000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14662000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
21819000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
32312000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
13646000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
48441000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8187000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16129000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
148000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
130000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18715000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1038000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18567000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
908000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7124000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2375000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14032000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10299000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21156000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12674000 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its portfolio of cash, cash equivalents and marketable securities. Under its investment policy, the Company limits amounts invested in such securities by credit rating, maturity, industry group, investment type and issuer, except for securities issued by the U.S. government. Cash is held at major banks in the United States. Therefore, the Company is not exposed to any significant concentrations of credit risk from these financial instruments. The goals of the Company's investment policy, in order of priority, are as follows: safety and preservation of principal and diversification of risk, liquidity of investments sufficient to meet cash flow requirements, and a competitive after-tax rate of return.</span></div>
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
37784000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
37796000 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
12000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
22766000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000 USD
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
22768000 USD
CY2020Q3 us-gaap Cash
Cash
18671000 USD
CY2019Q4 us-gaap Cash
Cash
11643000 USD
CY2020Q3 us-gaap Marketable Securities
MarketableSecurities
19113000 USD
CY2019Q4 us-gaap Marketable Securities
MarketableSecurities
11125000 USD
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
37784000 USD
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
22768000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearAmortizedCostBasis
37796000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Remainder Of Fiscal Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRemainderOfFiscalYearFairValue
37784000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveAmortizedCostBasis
0 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Maturities Rolling Year Two Through Five Fair Value
AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue
0 USD
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
37796000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
37784000 USD
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1784000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1834000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
359000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
354000 USD
CY2020Q3 clbs Accrued Grant Funding
AccruedGrantFunding
0 USD
CY2019Q4 clbs Accrued Grant Funding
AccruedGrantFunding
1600000 USD
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
933000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
698000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3076000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4486000 USD
CY2020Q3 clbs Number Of Offices Under Operating Leases
NumberOfOfficesUnderOperatingLeases
2 office
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
653000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
906000 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
710000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
977000 USD
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M6D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09625
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
103000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
414000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
239000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
27000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
783000 USD
CY2020Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
73000 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
710000 USD
CY2019Q2 clbs Aggregate Market Value Of Common Stock Non Affiliates
AggregateMarketValueOfCommonStockNonAffiliates
52800000 USD
CY2019Q4 clbs Common Stock Warrants Shares
CommonStockWarrantsShares
30000 shares
CY2019Q4 clbs Weighted Average Exercise Price Warrants Outstanding
WeightedAverageExercisePriceWarrantsOutstanding
5.89
CY2020Q1 clbs Weighted Average Remaining Contractual Termwarrantoutstanding
WeightedAverageRemainingContractualTermwarrantoutstanding
P3Y2M8D
CY2019Q4 clbs Aggregate Intrinsic Value Warrants Outstanding
AggregateIntrinsicValueWarrantsOutstanding
0 USD
clbs Warrants Granted
WarrantsGranted
2608355 shares
clbs Weighted Average Exercise Price Warrants Granted
WeightedAverageExercisePriceWarrantsGranted
2.14
clbs Warrants Exercised
WarrantsExercised
0 shares
clbs Weighted Average Exercise Price Warrants Exercised
WeightedAverageExercisePriceWarrantsExercised
0
clbs Warrants Canceled
WarrantsCanceled
0 shares
clbs Weighted Average Exercise Price Warrants Canceled
WeightedAverageExercisePriceWarrantsCanceled
0
clbs Warrants Expired
WarrantsExpired
0 shares
clbs Weighted Average Exercise Price Warrants Expired
WeightedAverageExercisePriceWarrantsExpired
0
CY2020Q3 clbs Common Stock Warrants Shares
CommonStockWarrantsShares
2638355 shares
CY2020Q3 clbs Weighted Average Exercise Price Warrants Outstanding
WeightedAverageExercisePriceWarrantsOutstanding
2.18
clbs Weighted Average Remaining Contractual Termwarrantoutstanding
WeightedAverageRemainingContractualTermwarrantoutstanding
P4Y11M23D
CY2020Q3 clbs Aggregate Intrinsic Value Warrants Outstanding
AggregateIntrinsicValueWarrantsOutstanding
0 USD
CY2020Q3 clbs Sharesvestedandexpectedtovest
Sharesvestedandexpectedtovest
2638355 shares
CY2020Q3 clbs Weighted Average Exercise Price Warrants Vested And Expected To Vest
WeightedAverageExercisePriceWarrantsVestedAndExpectedToVest
2.18
clbs Weighted Average Remaining Contractual Term Warrants Vestedand Expectto Vest
WeightedAverageRemainingContractualTermWarrantsVestedandExpecttoVest
P4Y11M23D
CY2020Q3 clbs Aggregate Intrinsic Value Warrantsvestedandexpectedtovest
AggregateIntrinsicValueWarrantsvestedandexpectedtovest
0 USD
CY2020Q3 clbs Warrants Vested
WarrantsVested
2638355 shares
CY2020Q3 clbs Weighted Average Exercise Price Warrants Exercisable
WeightedAverageExercisePriceWarrantsExercisable
2.18
clbs Weighted Average Remaining Contractual Termwarrantsvested
WeightedAverageRemainingContractualTermwarrantsvested
P4Y11M23D
CY2020Q3 clbs Aggregate Intrinsic Value Warrantsvested
AggregateIntrinsicValueWarrantsvested
0 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
229000 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
254000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1090000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1047000 USD
CY2017Q1 us-gaap Grants Receivable
GrantsReceivable
12200000 USD
CY2020Q3 us-gaap Grants Receivable
GrantsReceivable
8600000 USD
clbs Funding Of Grant Award Cash Received
FundingOfGrantAwardCashReceived
8200000 USD
CY2017Q2 clbs Funding Of Grant Award Cash Received
FundingOfGrantAwardCashReceived
5700000 USD
CY2017Q4 clbs Milestone Payment On Grant Award Cash Received
MilestonePaymentOnGrantAwardCashReceived
1900000 USD
CY2018Q1 clbs Progress Payment On Grant Award Cash Received
ProgressPaymentOnGrantAwardCashReceived
300000 USD
CY2019Q2 us-gaap Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred
ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
200000 USD
CY2020Q3 us-gaap Research And Development Arrangement With Federal Government Customer Funding To Offset Costs Incurred
ResearchAndDevelopmentArrangementWithFederalGovernmentCustomerFundingToOffsetCostsIncurred
46000 USD
CY2020Q3 clbs Amortization Of Accrued Grant Funding Liability To Offset Expense
AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
300000 USD
clbs Amortization Of Accrued Grant Funding Liability To Offset Expense
AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
1600000 USD
CY2019Q3 clbs Amortization Of Accrued Grant Funding Liability To Offset Expense
AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
700000 USD
clbs Amortization Of Accrued Grant Funding Liability To Offset Expense
AmortizationOfAccruedGrantFundingLiabilityToOffsetExpense
2000000.0 USD
CY2019Q4 clbs Market Capitalization Used In Net Operating Loss Analysis
MarketCapitalizationUsedInNetOperatingLossAnalysis
124500000 USD
CY2020Q1 clbs Net Operating Loss Analysis Annual Limitation
NetOperatingLossAnalysisAnnualLimitation
3000000.0 USD
CY2020Q2 clbs Sale Of Net Operating Losses Njeda Program Value
SaleOfNetOperatingLossesNJEDAProgramValue
11500000 USD
CY2020Q2 clbs Proceeds From Sale Of Net Operating Losses Njeda Program
ProceedsFromSaleOfNetOperatingLossesNJEDAProgram
10900000 USD

Files In Submission

Name View Source Status
0000320017-20-000110-index-headers.html Edgar Link pending
0000320017-20-000110-index.html Edgar Link pending
0000320017-20-000110.txt Edgar Link pending
0000320017-20-000110-xbrl.zip Edgar Link pending
clbs-20200930.htm Edgar Link pending
clbs-20200930.xsd Edgar Link pending
clbs-20200930_cal.xml Edgar Link unprocessable
clbs-20200930_def.xml Edgar Link unprocessable
clbs-20200930_htm.xml Edgar Link completed
clbs-20200930_lab.xml Edgar Link unprocessable
clbs-20200930_pre.xml Edgar Link unprocessable
clbs-ex31120200930xq3.htm Edgar Link pending
clbs-ex32120200930q3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending